Home > Insider Trading > Filing (0001209191-17-016933)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1492426	Horizon Pharma Plc	HZNP	Pharmaceutical Preparations (2834)	272179987

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1602064	Robert Carey	C/O Horizon Pharma Plc Connaught House, 1St Fl, 1 Burlington Rd Dublin L2 4	Evp, Chief Business Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Acquisiton	2017-02-28	6,913	$4.31	127,216	No	4	X	Indirect	By Robert F. Carey III Trust dated 4/24/2001
Ordinary Shares	Disposition	2017-02-28	1,808	$16.48	125,408	No	4	S	Indirect	By Robert F. Carey III Trust dated 4/24/2001
Ordinary Shares	Disposition	2017-03-01	30,000	$16.00	95,408	No	4	S	Indirect	By Robert F. Carey III Trust dated 4/24/2001

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	X	Indirect	By Robert F. Carey III Trust dated 4/24/2001
No	4	S	Indirect	By Robert F. Carey III Trust dated 4/24/2001
No	4	S	Indirect	By Robert F. Carey III Trust dated 4/24/2001

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Warrant to Purchase Ordinary Shares (Right to Buy)	Disposition	2017-02-28	6,913	$0.00	6,913	$4.31

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2012-03-02	2017-03-02	No	4	X	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Ordinary Shares	600	Direct

Footnotes

Includes 38,242 shares which were transferred from the Reporting Person to the Trust on January 11, 2017.
Exercise of a warrant to purchase 6,913 ordinary shares of the Issuer for $4.308 per share. The reporting person paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 1,808 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 5,105 shares. The warrant was scheduled to expire on March 2, 2017.
On June 1, 2016, 1,173 ordinary shares of the Issuer were acquired by the reporting person pursuant to an employee stock purchase program. The number of Issuer shares previously reported as beneficially owned by the reporting person was incorrectly over reported on a prior Form 4 by 573 shares of the Issuer's common stock, and has been corrected with this filing.